| Literature DB >> 32159421 |
Guoying Ni1,2,3, Lu Zhang1, Xiaodan Yang1, Hejie Li2,4, Bowei Ma1, Shelley Walton2, Xiaolian Wu5, Jianwei Yuan1, Tianfang Wang2, Xiaosong Liu1,2,5,6.
Abstract
Interleukin 10 (IL-10) belongs to IL-10 family cytokines that are critical for maintaining the integrity of epithelial tissues, protecting pathogenic infection, and preventing excessive immune responses to damage self. Temporal IL-10 signaling blockade enhances vaccine-induced tumor regression by CD8 + T cells. IL-10, especially pegylated IL-10, mediates tumor regression by expanding tumor-infiltrating CD8 + T cells. Moreover, targeting IL-10 enhances immune checkpoint inhibitor mediated tumor regression. In the current paper, we will review recent advances in this area and discuss the complexity of IL-10 manipulation for cancer therapy.Entities:
Keywords: Interleukin 10; PD-1; cancer immunotherapy
Mesh：
Substances：
Year: 2020 PMID： 32159421 PMCID： PMC7644214 DOI： 10.1080/21645515.2020.1717185
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 3.452